soluble trail recombinant protein Search Results


recombinant human trail  (ProSci Incorporated)
90
ProSci Incorporated recombinant human trail
Figure 2: Factors present in maternal plasma can induce apoptosis in Jurkat T-cells. A) Jurkat T-cells were cultured in the presence of Fas activating antibody CH11 (0.625 µg/mL), or <t>recombinant</t> <t>TRAIL</t> (3 ng/mL) and the level of early (DilC1(5)-PI-) and late (DilC1(5)-PI+) apoptosis determined by flow cytometry. Flow charts are representative of 3 separate experiments with similar results. B) Jurkat T-cells were cultured in the presence of 20% (v/v) non-pregnant (NP) or pregnant (P) plasma from individual patients for 72 hrs and the apoptosis determined. Pooled data from 5 individual patients (NP and P15-19) is indicated in the bar graph. C) Jurkat T-cells were pre-incubated for 1 hr in the presence of ZB4 (500 ng/mL) or anti-TRAIL (0.8 ng/mL) and subsequently cultured for 72 hrs in the presence of 20% (v/v) NP or P plasma. Apoptosis was determined by Flow cytometry. The level of early (DilC1(5)-PI-) apoptosis is shown on the graph where n=4 for both NP and P samples. *p<0.05 relative to NP plasma.
Recombinant Human Trail, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human trail/product/ProSci Incorporated
Average 90 stars, based on 1 article reviews
recombinant human trail - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
human soluble trail receptor-1 recombinant protein lyophilized  (Innovative Research Inc)
N/A
Human Soluble TRAIL Receptor-1 Recombinant Protein Lyophilized from Innovative Research has been recombinantly produced in E. coli. This is a Lyophilized protein buffered in with a purity of Greater than 98% by SDS-PAGE gel and
   Buy from Supplier
human soluble trail receptor-2 recombinant protein lyophilized  (Innovative Research Inc)
N/A
Human Soluble TRAIL Receptor-2 Recombinant Protein Lyophilized from Innovative Research has been recombinantly produced in E. coli. This is a Lyophilized protein buffered in with a purity of Greater than 98% by SDS-PAGE gel and
   Buy from Supplier
soluble trail receptor-1 recombinant protein  (Aviva Systems)
N/A
TRAIL Receptor-1/DR4 and TRAIL Receptor-2/DR5 belong to the TNFR superfamily of transmembrane proteins and contain a cytoplasmic "death domain, " which can activate the cell's apoptotic machinery. These receptors are activated by binding to either
   Buy from Supplier
soluble trail receptor-2 recombinant protein  (Aviva Systems)
N/A
TRAIL Receptor-1/DR4 and TRAIL Receptor-2/DR5 belong to the TNFR superfamily of transmembrane proteins and contain a cytoplasmic "death domain", which can activate the cell's apoptotic machinery. These receptors are activated by binding to either membrane
   Buy from Supplier
soluble trail receptor-2 recombinant protein  (ProSci Incorporated)
N/A
Human Soluble TRAIL Receptor-2 Recombinant Protein made in E. coli.
   Buy from Supplier
human / mouse trail, soluble recombinant protein ddddk tag lyophilized  (Innovative Research Inc)
N/A
Human / Mouse TRAIL, Soluble Recombinant Protein DDDDK Tag Lyophilized from Innovative Research has been recombinantly produced in E. coli. This is a Lyophilized protein buffered in Contains PBS. Reconstitute with 100 and#956;l sterile water.
   Buy from Supplier
soluble trail receptor-1 recombinant protein  (ProSci Incorporated)
N/A
Human Soluble TRAIL Receptor-1 Recombinant Protein made in E. coli.
   Buy from Supplier

Image Search Results


Figure 2: Factors present in maternal plasma can induce apoptosis in Jurkat T-cells. A) Jurkat T-cells were cultured in the presence of Fas activating antibody CH11 (0.625 µg/mL), or recombinant TRAIL (3 ng/mL) and the level of early (DilC1(5)-PI-) and late (DilC1(5)-PI+) apoptosis determined by flow cytometry. Flow charts are representative of 3 separate experiments with similar results. B) Jurkat T-cells were cultured in the presence of 20% (v/v) non-pregnant (NP) or pregnant (P) plasma from individual patients for 72 hrs and the apoptosis determined. Pooled data from 5 individual patients (NP and P15-19) is indicated in the bar graph. C) Jurkat T-cells were pre-incubated for 1 hr in the presence of ZB4 (500 ng/mL) or anti-TRAIL (0.8 ng/mL) and subsequently cultured for 72 hrs in the presence of 20% (v/v) NP or P plasma. Apoptosis was determined by Flow cytometry. The level of early (DilC1(5)-PI-) apoptosis is shown on the graph where n=4 for both NP and P samples. *p<0.05 relative to NP plasma.

Journal: Reproductive Immunology: Open Access

Article Title: NF-kB Regulation in T-cells in Pregnancy is Mediated via Fas/FasL Interactions: The Signal for which is Derived from Exosomes Present in Maternal Plasma

doi: 10.21767/2476-1974.100008

Figure Lengend Snippet: Figure 2: Factors present in maternal plasma can induce apoptosis in Jurkat T-cells. A) Jurkat T-cells were cultured in the presence of Fas activating antibody CH11 (0.625 µg/mL), or recombinant TRAIL (3 ng/mL) and the level of early (DilC1(5)-PI-) and late (DilC1(5)-PI+) apoptosis determined by flow cytometry. Flow charts are representative of 3 separate experiments with similar results. B) Jurkat T-cells were cultured in the presence of 20% (v/v) non-pregnant (NP) or pregnant (P) plasma from individual patients for 72 hrs and the apoptosis determined. Pooled data from 5 individual patients (NP and P15-19) is indicated in the bar graph. C) Jurkat T-cells were pre-incubated for 1 hr in the presence of ZB4 (500 ng/mL) or anti-TRAIL (0.8 ng/mL) and subsequently cultured for 72 hrs in the presence of 20% (v/v) NP or P plasma. Apoptosis was determined by Flow cytometry. The level of early (DilC1(5)-PI-) apoptosis is shown on the graph where n=4 for both NP and P samples. *p<0.05 relative to NP plasma.

Article Snippet: To assess the role of FasL and TRAIL activation in regulating p65 expression and apoptosis cells were incubated in the presence of the Fas activating antibody CH11 (Millipore) or recombinant human TRAIL (ProSci) at concentrations stated in the figure legends.

Techniques: Clinical Proteomics, Cell Culture, Recombinant, Flow Cytometry, Incubation

Figure 3: Factors present in maternal plasma can induce suppression of p65 in T-cells; A) Jurkat T-cells were cultured in the presence of increasing concentrations of Fas activating antibody CH11 or recombinant TRAIL and the level of p65 determined. Blot is representative of 3 separate experiments with similar results; B) Jurkat T-cells were cultured in the presence of CH11 (0.625 µg/mL) ±500 ng/mL Fas inactivating antibody ZB4 or mIgG control or IgM control (0.625 µg/mL) or recombinant TRAIL (3 ng/mL) ±80 ng/mL anti-TRAIL or mIgG control or BSA (3 ng/mL) and the level of p65 determined. Blot is representative of 3 separate experiments with similar results; C) Jurkat T-cells were cultured in the presence of CH11 (0.625 µg/mL) ±500 ng/mL Fas inactivating antibody ZB4 or mIgG control or IgM control (0.625 µg/mL) and the level of p65 and CD3ζ determined in cell lysates. Blot is representative of 3seperate experiments each showing similar results.

Journal: Reproductive Immunology: Open Access

Article Title: NF-kB Regulation in T-cells in Pregnancy is Mediated via Fas/FasL Interactions: The Signal for which is Derived from Exosomes Present in Maternal Plasma

doi: 10.21767/2476-1974.100008

Figure Lengend Snippet: Figure 3: Factors present in maternal plasma can induce suppression of p65 in T-cells; A) Jurkat T-cells were cultured in the presence of increasing concentrations of Fas activating antibody CH11 or recombinant TRAIL and the level of p65 determined. Blot is representative of 3 separate experiments with similar results; B) Jurkat T-cells were cultured in the presence of CH11 (0.625 µg/mL) ±500 ng/mL Fas inactivating antibody ZB4 or mIgG control or IgM control (0.625 µg/mL) or recombinant TRAIL (3 ng/mL) ±80 ng/mL anti-TRAIL or mIgG control or BSA (3 ng/mL) and the level of p65 determined. Blot is representative of 3 separate experiments with similar results; C) Jurkat T-cells were cultured in the presence of CH11 (0.625 µg/mL) ±500 ng/mL Fas inactivating antibody ZB4 or mIgG control or IgM control (0.625 µg/mL) and the level of p65 and CD3ζ determined in cell lysates. Blot is representative of 3seperate experiments each showing similar results.

Article Snippet: To assess the role of FasL and TRAIL activation in regulating p65 expression and apoptosis cells were incubated in the presence of the Fas activating antibody CH11 (Millipore) or recombinant human TRAIL (ProSci) at concentrations stated in the figure legends.

Techniques: Clinical Proteomics, Cell Culture, Recombinant, Control